S. Lechner

Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration

C. Rivolta, Min Zhao, I. Mantel, 2019, Nature Communications.

IgA1 Protease Treatment Reverses Mesangial Deposits and Hematuria in a Model of IgA Nephropathy.

S. Lechner, A. Jamin, P. Martini, 2016, Journal of the American Society of Nephrology : JASN.

Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction.

S. Lechner, E. Daugas, F. Vrtovsnik, 2015, Kidney international.

Role of IgA receptors in the pathogenesis of IgA nephropathy

S. Lechner, R. Monteiro, L. Berthelot, 2016, Journal of Nephrology.

Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury–Mediated Chronic Kidney Disease: Role of Oxidative Stress

S. Lechner, F. Jaisser, N. Bobadilla, 2017, Hypertension.

Experimental Autoimmune Encephalomyelitis Develops in CC Chemokine Receptor 7‐deficient Mice with Altered T‐cell Responses

R. Maki, S. Lechner, P. Hevezi, 2006, Scandinavian journal of immunology.

The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling.

S. Lechner, F. Jaisser, P. Kolkhof, 2018, Kidney international.

Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1.

S. Lechner, F. Jaisser, A. Nguyen Dinh Cat, 2017, Journal of the American Society of Nephrology : JASN.

IgA1 Protease Treatment Reverses Mesangial Deposits and Hematuria in a Model of IgA Nephropathy.

S. Lechner, A. Jamin, P. Martini, 2016, Journal of the American Society of Nephrology : JASN.